[PDF][PDF] Pharmacokinetics and Scintigraphy of Indium 111-DTPA-MOC-31 in Small-Cell Lung Carcinoma

L de Leij, JGW Kosterink, MWA de Jonge… - Journal of Nuclear …, 1995 - Soc Nuclear Med
Radiolabeled MOC-31 retains its immunoreactivity and shows good in vivo
immunolocalizationto human SCLC xenografted in nude rats. Methods: We evaluatedthe …

Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31

MWA de Jonge, JGW Kosterink, YY Bin… - European Journal of …, 1993 - Elsevier
The applicability of mouse monoclonal antibody MOC-31 for in vivo radioimmunodetection
of human small cell lung cancer (SCLC) was investigated in a nude rat xenograft model …

A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.

M Arnedos, CS Denlinger, WA Harb, O Rixe, JC Morris… - 2013 - ascopubs.org
2609 Background: MM-121 is a fully human monoclonal antibody targeting the epidermal
growth factor receptor family member ErbB3. ErbB3 has been implicated in driving cancer …

Radiolabeling, biodistribution, and dosimetry of 123I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo

CMM Lahorte, K Bacher, I Burvenich… - Journal of Nuclear …, 2004 - Soc Nuclear Med
This study reports on the in vitro evaluation, biodistribution, and dosimetry of 123I-labeled
monoclonal antibody (mAb) 14C5, a new antibody-based agent proposed for …

Phase I Study of 90Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co …

A Forero, RF Meredith, MB Khazaeli… - Cancer biotherapy & …, 2005 - liebertpub.com
Purpose: This trial was designed to evaluate strategies to improve the efficacy of a
radiolabeled monoclonal antibody (mCC49) against tumor-associated glycoprotein-72 (TAG …

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

AM Traynor, MS Gordon, D Alberti… - Investigational new …, 2010 - Springer
Purpose: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety,
and tolerability of MN-209, a novel vascular disrupting agent, in patients with advanced solid …

First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion …

N Pandit-Taskar, MA Postow… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Immunotherapy is becoming the mainstay for treatment of a variety of malignancies, but only
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …

Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models

L Yu, Y Yao, Y Wang, S Zhou, Q Lai, Y Lu… - Journal of Drug …, 2018 - Taylor & Francis
Antibody-drug conjugates (ADCs) have been successfully applied clinically as target drugs
for cancer. In this study, anti-neural cell adhesion molecule also called CD56 antibody …

A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

MS Ernstoff, WW Ma, FYC Tsai, PN Munster, T Zhang… - 2018 - ascopubs.org
TPS2604 Background: Ephrin receptor A2 (EphA2) is expressed in cancer and stroma cells
in a wide range of solid tumors. MM-310 is an EphA2-targeting liposomal form of a docetaxel …

Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer

F Kraeber-Bodéré, A Mishra, P Thédrez… - European journal of …, 1996 - Springer
The use of samarium-153 in the context of radioimmunotherapy of cancers has been limited
by the instability of antibody labelling, which produces high uptake concentrations in liver …